> DIFF VIEW / 05
Tesamorelin vs Sermorelin: Structure and Evidence Compared
A structural diff of two GHRH analogues — the full-length, DPP-IV-resistant GHRH(1-44) against the truncated GHRH(1-29) — and an honest read on how different their published evidence bases are.
In plain English
Tesamorelin vs sermorelin is, at bottom, long versus short. Both are lab copies of GHRH (the brain's "make growth hormone" signal), and both tell the pituitary to release the body's own growth hormone. Sermorelin is a shortened version — the first 29 amino acids, GHRH(1-29). Tesamorelin keeps all 44 and adds a chemical cap that stops the body from breaking it down so fast [1]. The bigger practical gap is evidence: tesamorelin has large randomized trials and an FDA approval for one HIV use [1][5], whereas sermorelin's modern research base is far thinner. This page diffs the two — it does not recommend either.
The structural diff: GHRH(1-44) vs GHRH(1-29)
Both molecules are analogues of human growth hormone-releasing hormone, and both act as agonists at the GHRH receptor on pituitary somatotrophs — so the upstream mechanism is shared. The diff is sequence length and stability.
Tesamorelin is the full-length GHRH(1-44) sequence carrying a trans-3-hexenoic acid cap on its N-terminus; that cap blocks DPP-IV, the protease that inactivates native GHRH within minutes, giving tesamorelin a longer functional window [1]. Sermorelin is the truncated GHRH(1-29) — the shortest fragment that retains full GHRH biological activity — without that stabilizing modification, so it is more rapidly degraded. In a terminal's terms: same receptor target, but tesamorelin is the longer payload with a protective wrapper, and sermorelin is the minimal active fragment. The full-length-plus-cap design is the structural reason tesamorelin sustains a measurable IGF-1 elevation across a once-daily interval [11].
Attribute by attribute
Laid out as a diff, the shared rows and the differing rows separate cleanly. Receptor target: identical — both are GHRH-receptor agonists acting on pituitary somatotrophs [4]. Mechanism class: identical — both raise the body's own pulsatile GH and downstream IGF-1 rather than supplying exogenous GH [11]. Those are the matched lines.
The diverging lines are sequence and stability. Sequence: tesamorelin is the full-length GHRH(1-44); sermorelin is the truncated GHRH(1-29) [1]. DPP-IV resistance: tesamorelin carries the N-terminal trans-3-hexenoic acid cap that blocks DPP-IV cleavage; sermorelin lacks that modification and is degraded more rapidly [1][4]. Molecular weight: tesamorelin's free base is 5135.9 Da [1]. Studied dose and route: tesamorelin's characterized regimen is 2 mg subcutaneously once daily [1][2]. Regulatory status: tesamorelin is FDA-approved for HIV-associated lipodystrophy (NDA 022505, 2010) [5]; both are WADA-prohibited (category S2). The structural choices on the tesamorelin row — full length plus a protective cap — are what give it the sustained once-daily IGF-1 signal documented in the PK-PD model [11].
The evidence diff: depth of the published record
The larger practical difference is the weight of evidence behind each. Tesamorelin's record is unusual for this compound class: two pivotal Phase 3 RCTs in HIV-associated lipodystrophy (the n=412 pivotal trial [1] and the 52-week program [2][6]), a JAMA RCT in HIV hepatic steatosis [3], a mechanistic study in healthy men [4], a pooled predictor analysis [10], a population PK-PD model [11], and a 2026 five-RCT meta-analysis [13] — culminating in FDA approval for the HIV indication in 2010 [5].
Sermorelin's modern published efficacy base is comparatively sparse, and this site does not catalogue it. What can be said precisely is the asymmetry: when a reader asks "tesamorelin vs sermorelin," they are comparing a compound with a deep, FDA-reviewed randomized-trial record in one specific population against a truncated analogue with a much thinner contemporary evidence base. The comparison here is structural and evidentiary, not a clinical endorsement of either, and neither is presented as a medicine to self-administer.
What the comparison does not establish
A structural and evidentiary diff is not a head-to-head trial. No randomized study in this record directly compared tesamorelin against sermorelin for any outcome, so any claim that one "outperforms" the other for fat loss, GH elevation, or safety would be an extrapolation the data does not support.
The scope caveats on tesamorelin still apply in full: its measured benefits are in HIV-associated lipodystrophy [1][2], the visceral fat reaccumulates on discontinuation [2][6], FDA approval covers that one indication only [5], and it is WADA-prohibited in sport (category S2). The honest summary of tesamorelin vs sermorelin is a contrast of design and evidence depth — read the side effects and contraindications before drawing any further conclusion.